Fact Sheet

Master Protocol Unit

Mastering complexity in adaptive clinical trials

Accelerate your success with master protocols

Adaptive trials, such as master protocols, improve efficiency, evidence generation, and data analysis in modern drug development. Master protocols enable testing multiple therapies within one flexible, simplified design, cutting time and costs to bring treatments to patients faster. Once concentrated on oncology, neurology and rare diseases, they are now reshaping clinical research across diverse indications. While offering greater efficiency and speed, these designs add complexity that demands careful processes and skilled teams.

Meeting the challenges of the master platform study lifecycle



The IQVIA Biotech Master Protocol Unit: your strategic partner

Purpose-built for the complexities of master protocol delivery, the **IQVIA Biotech Master Protocol Unit (MPU)** provides innovative, efficient and scalable clinical trial solutions tailored to the unique demands of master protocols and platform studies. Our specialized team focuses on streamlining processes and optimizing delivery to ensure speed, accuracy and flexibility while helping you achieve success in a highly dynamic environment.

Key drivers of functional efficiency in master protocols

- Shared trial infrastructure and resources
- Enhanced data integration
- Centralized systems
- Streamlined site management and communication

Master protocol operationalization

The MPU offers a strategic advantage for complex trial designs, drawing on proven expertise in master protocol execution. By combining operational processes with exceptional agility, the MPU accelerates success from planning and development through implementation and governance. The unit provides comprehensive solutions that ensure precision, scalability and regulatory confidence. Cross-functional collaboration and resource optimization are at the forefront, offering sponsors confidence and clarity in an increasingly competitive landscape.

Unmatched experience for sponsors and patients

105 **master protocol studies** conducted

13,000 **patients** enrolled across nearly **2,000 sites**

67 **countries** with operations

Driving innovation in adaptive trials

IQVIA Biotech is committed to advancing the conduct of adaptive trials through innovative approaches and best-in-class operational excellence.

IQVIA Biotech Master Protocol Unit (MPU)



The IQVIA Biotech difference

The MPU leadership team delivers oversight across all master protocol trials, ensuring alignment, quality and continuity throughout each study. Built on a strong protocol foundation designed for complexity and adaptability, our approach turns the protocol into a long-term strategic asset. By partnering with the IQVIA Biotech MPU, sponsors gain access to deep global expertise, integrated IQVIA capabilities, and advanced analytics that enable faster decision-making. We have the experience to push the boundaries of traditional clinical development to anticipate challenges, adapt to change and help you succeed.

IQVIA BIOTECH

CONTACT US

iqviabiotech.com